Bormioli Pharma, leading global producer in the pharma packaging market, announced today the strengthening of its presence in the US, establishing a new legal entity – named Bormioli Pharma United States Inc. – in the United States.
This decision is part of the company’s five-year strategic plan and sees the opening of a commercial branch in Philadelphia, hosting an on-site sales team dedicated to the North American market.
Andrea Lodetti, CEO Bormioli Pharma, commented: “Through our internationalization strategy, we aim to be closer to our customers, providing a more effective service for the biggest pharma market in the world. That’s part of our growth strategy plan, aiming to make Bormioli Pharma a truly global player, able to answer to the market challenges with high value-added pharma packaging solutions.”
Acquired in November 2017 by the investment fund Triton, Bormioli Pharma is now a forward-looking independent company showing considerable growth and able to compete on a global scale.
Internationalization is one of the pillars of Bormioli Pharma’s growth strategy, together with the development of a new, outstanding innovation model, and the optimization of the company’s core business.
Bormioli Pharma also plans to strengthen its overseas logistics support through the opening a new warehouse in the United States, scheduled by H1 2019.
